The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | The pivotal ZUMA-1 trial for NHL
Sattva Neelapu, MD from the MD Anderson Cancer Center, Houston, TX gives an overview of his work on the development of KTE-C19, a CAR T-cell developed for relapsed/refractory non-Hodgkin lymphoma (NHL). Here, he provides a detailed explanation of the development of the ZUMA-1 trial (NCT02348216). The results of the trial have been promising in terms of overall and complete response rates as well as remission. This interview was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
